

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和鉑醫藥控股有限公司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT
FOOD AND DRUG ADMINISTRATION OF THE UNITED STATES IND
CLEARANCE FOR HBM9027 CLINICAL TRIAL INITIATION

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company has been granted the clearance of Investigational New Drug (the “**IND**”) from the Food and Drug Administration of the United States (FDA) to initiate the First-in human (FIH) clinical trials in the U.S. for HBM9027, our bispecific antibody. This is a Phase I study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of HBM9027 in subjects with advanced solid tumors.

HBM9027 is generated from the Group’s proprietary fully human HBICE® platform. It is a novel PD-L1xCD40 bispecific antibody, which is designed to activate CD40 relied on PD-L1 crosslinking for a promising safety profile. PD-L1 is overexpressed on a variety of solid malignancies, with its crosslinking dependent specificity on tumors and potent immune modulation activity, HBM9027 has shown excellent safety profile with strong anti-tumor efficacy in the pre-clinical studies.

About HBM9027

As set out above, HBM9027 is a novel PD-L1xCD40 bispecific antibody, developed using the Group’s HBICE® bispecific technology and Harbour Mice® Platform. The development of PD-L1xCD40 bispecific HBICE® further expands our bispecific immune cell engager into the cutting-edge DC/myeloid cell engager field and demonstrates HBICE® Platform’s versatile geometry formats and plug-and-play advantages.

Cautionary Statement: We cannot guarantee that we will be able to successfully develop or ultimately market HBM9027. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 24 January 2024

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Ms. Weiwei Chen as non-executive Director; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Mr. Ka Chi Yau and Dr. Albert R. Collinson as independent non-executive Directors.